Dihydropyrimidinase Polyclonal Antibody, FITC Conjugated
Applications
Predicted Reactivity
| Overview | |
| Catalog # | bs-8287R-FITC |
| Product Name | Dihydropyrimidinase Polyclonal Antibody, FITC Conjugated |
| Applications |
WB
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Predicted Reactivity | Human, Mouse, Rat, Dog, Cow, Sheep, Chicken |
| Specifications | |
| Conjugation | FITC |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human DHP/Dihydropyrimidinase |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 1807 |
| Subcellular location | Cytoplasm, Secreted, Extracellular matrix |
| Synonyms | DHP; DHPase; Dihydropyrimidinase; Dihydropyrimidine amidohydrolase; Dpys; DPYS_HUMAN; Hydantoinase. |
| Background | Catalyzes the second step of the reductive pyrimidine degradation, the reversible hydrolytic ring opening of dihydropyrimidines. Can catalyzes the ring opening of 5,6-dihydrouracil to N-carbamyl-alanine and of 5,6-dihydrothymine to N-carbamyl-amino isobutyrate.Tissue specificity:Liver and kidney.Involvement in disease:Defects in DPYS are the cause of dihydropyrimidinase deficiency (DHPD). DHPD is an autosomal recessive disorder characterized by dihydropyrimidinuria and associated with a variable clinical phenotype: epileptic or convulsive attacks, dysmorphic features and severe developmental delay, and congenital microvillous atrophy. |
| Application Dilution | |
| WB | 1:300-5000 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |
Frequently asked questions
Which applications is Dihydropyrimidinase Polyclonal Antibody, FITC Conjugated (bs-8287R-FITC) validated for, and at what dilution?
bs-8287R-FITC is validated for WB (1:300-5000); IF(IHC-P) (1:50-200); IF(IHC-F) (1:50-200); IF(ICC) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
How should bs-8287R-FITC be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise Dihydropyrimidinase Polyclonal Antibody, FITC Conjugated (bs-8287R-FITC)?
KLH conjugated synthetic peptide derived from human DHP/Dihydropyrimidinase
What are the excitation and emission wavelengths of the FITC conjugate (bs-8287R-FITC)?
FITC on bs-8287R-FITC: excitation / emission 494nm/518nm.